Affle 3I Fund Raise of ₹1,100 Cr

Affle 3I Acquisition Worth ₹3,990 Cr

Affle 3i's step-down subsidiary will acquire Perion Network in an all-cash deal valued at about ₹3,990 Crore. Closing is expected in early 2027.

Value

₹3,990 Cr

Execution

Expected to close in early 2027

Affle 3I Results Update

Affle 3i reports Q2 FY2027 revenue of Rs 783.6 crore, up 21.2% y-o-y, with EBITDA up 24.2%. PAT rose 17.4% to Rs 129.8 crore.

Affle 3I Investor Presentation: Key Takeaways

Q2 FY27 revenue INR 7,836 mn (+21.2% YoY), EBITDA INR 1,814 mn (23.2% margin), PAT INR 1,298 mn (+17.4%). H1 revenue +20.8%, PAT +19.5%. CPCU conversions +18.2% YoY.

Affle 3I Q2 FY27 Results: Net Profit ₹129.8 Cr, Up 17.5% YoY

Affle 3I Ltd reported revenue from operations of ₹783.6 Cr (+21.2% YoY) and net profit of ₹129.8 Cr (+17.5% YoY) for Q2 FY27.

Key figure

Net profit ₹129.8 Cr · +17.5% YoY

Affle 3I Board Meeting Date

Affle 3i will hold a board meeting on 30 October 2026 to consider unaudited standalone and consolidated results for the quarter and half year ended September 2026. This is a prior intimation, so the results are not yet approved.

Affle 3I Other Announcement

Affle 3i Ltd filed its quarterly shareholding pattern as of 19 October 2026. The filing reflects warrant-conversion share allotments to Affle Holdings.

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026

Sudarshan Pharma Industries Fund Raise

Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.

GAIL (India) Fund Raise

GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.